Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis

Fig. 1

Time to progression. Kaplan-Meier curves indicating the time to progression in all patients receiving only everolimus + lanreotide (n = 56)* or sunitinib + lanreotide (n = 50), in patients with pNETs receiving everolimus + lanreotide (n = 26)* or sunitinib + lanreotide (n = 28), and in patients with extrapancreatic neuroendocrine tumours receiving everolimus + lanreotide (n = 30) or sunitinib + lanreotide (n = 22). *Information on tumour progression was missing in 1 patient receiving everolimus + lanreotide

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us